Romero-Gmez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS, Group (2023) A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with nonalcoholic fatty liver disease
Some users notice warming sensations near injection sites, possibly related to increased local blood flow from nitric oxide effects
Sans conservateurs
Geetika Arora, an endocrinologist at Northwell's Phelps Hospital, puts it simply: "The trade-off comes down to convenience versus maximum weight loss." In a Lilly-funded trial published by The Lancet, patients on 12 to 36 milligrams of orforglipron lost an average of 15 to 20 pounds, compared with 8 to 11 pounds for those on 7 to 14 milligrams of Rybelsus
Neuroinflammation 15, 112
[15] Tirzepatide is currently licensed in the UK for type 2 diabetes (as Mounjaro)